[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Hôpital Européen Marseille\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":185},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,41,63,85,103,123,142,166],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100630718","is-post-exertional-symptom-exacerbation-specific-to-patients-with-myalgic-encephalomyelitis--chronic-fatigue-syndrome-a-study-comparing-patients-with-myalgic-encephalomyelitis--chronic-fatigue-syndrome-and-patients-with-cardiac-diseases-who-underwent-an-exercise-test-100630718",false,"NCT07491315","Is Post-exertional Symptom Exacerbation Specific to Patients With Myalgic Encephalomyelitis \u002F Chronic Fatigue Syndrome? A Study Comparing Patients With Myalgic Encephalomyelitis \u002F Chronic Fatigue Syndrome and Patients With Cardiac Diseases Who Underwent an Exercise Test.","MAPEMCAR","Inclusion Criteria:\n\n* Aged ≥ 18 years\n* For patients with Myalgic Encephalomyelitis \u002F Chronic Fatigue Syndrome (ME\u002FCFS): Clinical diagnosis of Myalgic Encephalomyelitis \u002F Chronic Fatigue Syndrome according to the International Consensus Criteria (ICC) 2011.\n* For patients with cardiac diseases : patients referred for an exercise test in the cardiology department for one of the following indications: palpitations, hypertension, exertional dyspnea, chest pain, cornoray artery disease and presence of moderate to severe fatigue defined as a Numerical Rating Scale (NRS) \\> 3\u002F10 during the last 8 days and no diagnosis of Myalgic Encephalomyelitis \u002F Chronic Fatigue Syndrome.\n* Ability to use a computer or digital device required to complete online questionnaires.\n* Having given free and informed written consent\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding woman\n* Persons deprived of their liberty by a judicial or administrative decision.\n* Persons who are subject to a legal protection measure or who are unable to express their consent.","ALL","18 Years",{"count":19,"type":20},80,"ESTIMATED","INTERVENTIONAL",[23],"NA","Myalgic Encephalomyelitis \u002F Chronic Fatigue Syndrome (ME\u002FCFS) is a disease characterized by persistent and unexplained fatigue associated with diffuse pain, sleep disorders, neurocognitive and autonomic symptoms, musculoskeletal manifestations and digestive symptoms. A central feature of this disease is post-exertional symptom exacerbation, also referred to as post-exertional malaise, defined as the worsening or the appearance of symptoms after physical or mental exertion, sometimes even minimal.\n\nSeveral studies have described post-exertional malaise in populations of patients with ME\u002FCFS following a standardized exercise test performed over one or two consecutive days. These studies confirmed the presence of post-exertional malaise in ME\u002FCFS patients compared with healthy controls or patients with multiple sclerosis.\n\nHowever, no data are available evaluating the impact of an exercise test on symptoms in patients referred to cardiology for this examination. Patients with cardiac diseases may also present symptoms such as fatigue, dyspnea or exercise intolerance.\n\nThis study aims to compare post-exertional symptoms in two populations: patients with ME\u002FCFS and patients with cardiac diseases undergoing an exercise test as part of routine clinical evaluation. The study also aims to measure variations in muscle oxyhemoglobin and deoxyhemoglobin concentrations before, during and after exercise using Near Infrared Spectroscopy (NIRS).",[26,27],"Fatigue Syndrome, Chronic","Cardiovascular Diseases","RECRUITING","2026-06-04",{"date":31,"type":32},"2026-06-08","ACTUAL",{"date":34,"type":32},"2025-06-24",{"date":36,"type":20},"2026-12-24",{"name":38,"class":39},"Hôpital Européen Marseille","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":21,"phases":51,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":40},"100625395","impact-of-ercs-on-perceived-stress-in-patients-hospitalized-in-the-post-resuscitation-rehabilitation-service-100625395","NCT07422077","Impact of ERCS on Perceived Stress in Patients Hospitalized in the Post-resuscitation Rehabilitation Service","Impact of Energy Resonance by Skin Stimulation on Perceived Stress in Patients Hospitalized in the Post-resuscitation Rehabilitation Service","IRESC","Inclusion Criteria:\n\n* Aged ≥ 18 years\n* Hospitalized adults in a Post-Intensive Care Rehabilitation Unit (SRPR)\n* Having given free and informed written consent\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding woman\n* Persons deprived of their liberty by a judicial or administrative decision.\n* Persons who are subject to a legal protection measure or who are unable to express their consent.",{"count":50,"type":20},38,[23],"Surviving an intensive care unit hospitalization (ICU) can be the beginning of a long rehabilitation journey, hindered by symptoms of stress, PTSD, anxiety, and depression. In order to improve the care of these patients, it's essential to explore effective non-pharmacological approaches to reduce stress. Many non-drug techniques are being developed to alleviate the physical and psychological pain of patients.\n\nEnergy Resonance by Skin Stimulation (ERCS) is a noninvasive method of soothing and supporting the patient. This technique is based on the energetic principles of traditional Chinese medicine. It relies on a \"listening contact\" through the stimulation of cutaneous points to create resonance and transmit vibrational and wave messages in the tissues. ERCS has various applications, whether for the management of acute or chronic pain, emotional disorders such as fear, anxiety, and depression.\n\nOur study aims to assess the effects of ERCS on the perceived stress of patients hospitalized in the post-ICU rehabilitation service. By demonstrating its potential impact on both physical and psychological recovery, this research could support the integration of RESC into care protocols and open new perspectives for stress management in hospital settings",[54],"Stress Disorders, Post-Traumatic","2026-02-18",{"date":57,"type":32},"2026-02-19",{"date":59,"type":32},"2025-12-08",{"date":61,"type":20},"2027-09-08",{"name":38,"class":39},{"id":64,"slug":65,"hasResults":11,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":69,"eligibilityCriteria":70,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":71,"targetDuration":4,"studyType":73,"phases":4,"briefSummary":74,"conditions":75,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":40},"100462566","evolution-of-hiv-reservoir-inflammation-and-microbiota-footprint-of-plwh-switching-to-long-acting-injectable-treatment-compared-to-patients-on-oral-dual-or-triple-anti-integrase-based-therapy-100462566","NCT05303337","Evolution of HIV Reservoir, Inflammation and Microbiota Footprint of PLWH Switching to Long-acting Injectable Treatment Compared to Patients on Oral Dual or Triple Anti-integrase-based Therapy","Evolution of HIV Reservoir, Inflammation and Microbiota Footprint of PLWH Switching to Long-acting Injectable Treatment Compared to Patients on Oral Dual or Triple Anti-integrase-based Therapy: a Prospective Longitudinal Comparative Study","LAMIVIH","Inclusion Criteria:\n\n* PLWH at a the stable phase of their disease (absence of disease outbreak and absence of treatment modification in the 3 months preceding inclusion),\n* Subject with ongoing HIV follow-up on an outpatient basis (outpatient or day hospital consultation) in the participating center, and having virological suppression at the threshold of 50 copies \u002F mL for at least 1 year (blips \\\u003C 200 copies \u002F mL tolerated during this period)\n* CD4 + T cell nadir\\> 200 \u002F mm3\n* Having given free and informed written consent\n* Being affiliated with or benefiting from a social security scheme.\n\nExclusion Criteria:\n\n* Persons treated with antibiotics, probiotics, prebiotics or any other treatment that may disrupt the gut microbiota within two month before stool sampling.\n* Subject only coming for full impatient follow-up",{"count":72,"type":20},120,"OBSERVATIONAL","In the last 40 years of HIV history, we have managed to attain most of our therapeutic objectives, namely virological suppression of most patients and sufficient immune reconstitution. Still, immune activation and inflammation persist and even if they decrease on ART (AntiRetroviral Treatment), they do not disappear and may be associated to multiple non-AIDS related comorbidities.\n\nIn this population structural and functional modifications of GALT (Gut Associated Lymphoïd Tissue) are observed early after HIV infection and persist despite virological suppression on ART. Moreover, imbalance of the gut microbiota which is called dysbiosis may participate in persistent activation and therefore enhancement of residual HIV viral replication.\n\nGALT modifications are associated with microbial translocation that is also correlated with immune activation and dysbiosis.\n\nUp to now, there is no evidence of a differential impact on inflammation, immune activation or cellular reservoirs of different ART regimens. Long-Acting (LA) regimens could theoretically display better inflammatory profile, since they have a better tissue distribution and could act more efficiently on HIV reservoirs. On the other hand, LA's direct administration shunting the gut passage could also contribute to less gut dysbiosis.\n\nThe objective of our study is to assess impact on plasma biomarkers, cell-surface biomarkers, intestinal microbiota and cellular reservoirs of a switch from an oral dual or triple anti-integrase-based therapy ART regimen including an anti-integrase compared to a Long-Acting (LA) injectable treatment.",[76],"HIV Infections","2025-09-24",{"date":79,"type":32},"2025-09-25",{"date":81,"type":32},"2022-04-11",{"date":83,"type":20},"2026-03",{"name":38,"class":39},{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":89,"acronym":90,"eligibilityCriteria":91,"healthyVolunteers":11,"sex":16,"minAge":92,"maxAge":4,"enrollmentInfo":93,"targetDuration":4,"studyType":73,"phases":4,"briefSummary":95,"conditions":96,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":97,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":40},"100445324","microbiota-footprint-and-frailty-phenotype-in-virologically-suppressed-people-living-with-hiv-100445324","NCT05078957","Microbiota Footprint and Frailty Phenotype in Virologically Suppressed People Living With HIV","FRAMIVIH","Inclusion Criteria:\n\n* Individuals infected with HIV in the stable phase of their disease (absence of disease outbreak and absence of therapeutic modification within 3 months before inclusion),\n* Subject with ongoing HIV follow-up on an outpatient basis (outpatient or day hospital consultation) in the participating center, and having virological suppression at the threshold of 50 copies \u002F mL for at least 5 years (tolerance of blips \\\u003C 200 copies \u002F mL during this period)\n* Aged ≥ 55 at baseline\n* CD4 + T cell nadir\\> 200 \u002F mm3\n* Giving free and informed written consent\n* Being affiliated with or benefiting from a social security scheme.\n\nExclusion Criteria:\n\n* Persons treated with antibiotics, probiotics, prebiotics or any other treatment that may disrupt the gut microbiota within two months before stool sampling.\n* Subject not followed regularly in the participating center,\n* Subject only coming for full hospitalization\n* Subject in the primary infection phase of less than 1 year","55 Years",{"count":94,"type":20},132,"Analysis of gut microbiota becomes more and more accessible in recent years. Experimental data in both animal and human studies have demonstrated that imbalance of the gut microbiota which is called symbiosis may participate in an accelerated procedure of ageing as well as the expression of frailty phenotype. People living with HIV (PLHIV) present markers of phenotypic frailty on average 10 years before uninfected people.\n\nIn this population structural and functional modifications of GALT (Gut Associated Lymphoid Tissue) are observed early after HIV infection and persist despite virological suppression on ART (AntiRetroviral Treatment). These GALT modifications are associated with microbial translocation that is also correlated with immune activation and dysbiosis.\n\nThe objective of study is to explore gut microbiota of PLWH over 5 years, as well as to study associations of its longitudinal evolution with frailty markers and burden of comorbidities.",[76],{"date":79,"type":32},{"date":99,"type":32},"2023-12-05",{"date":101,"type":20},"2030-03",{"name":38,"class":39},{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":109,"eligibilityCriteria":110,"healthyVolunteers":111,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":112,"targetDuration":4,"studyType":21,"phases":113,"briefSummary":114,"conditions":115,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":117,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":40},"100431520","analysis-of-intestinal-microbiota-as-a-predictor-of-response-to-treatment-of-spondyloarthritis-with-biotherapy-100431520","NCT04899154","Analysis of Intestinal Microbiota as a Predictor of Response to Treatment of Spondyloarthritis With Biotherapy","MEDIBIOTE 3: Analysis of Intestinal Microbiota as a Predictor of Response to Treatment of Spondyloarthritis With Biotherapy","MEDIBIOTE 3","Inclusion Criteria:\n\nFor patient with spondyloarthritis:\n\n* Diagnosed for spondyloarthritis or pure axial or axial type psoriatic rheumatism according to Assessment of Spondyloarthritis International Society (ASAS) criteria.\n* Requiring treatment with anti-TNFα or anti- IL-17 according to the treatment recommendations of the French Society of Rheumatology (SFR)\n* patient not previously treated with biotherapy\n* Aged ≥ 18 years\n* Having given free and informed written consent\n* Being affiliated to the center national security system social\n\nFor control Subject:\n\n* Healthy volunteers without diagnosis of spondyloarthritis or any other chronic disease.\n* Aged ≥ 18 years\n* Having given free and informed written consent\n* Being affiliated with or benefiting from a social security scheme.\n\nExclusion Criteria:\n\n* Persons treated with antibiotics, probiotics, prebiotics or any other treatment that may disrupt the gut microbiota within one month before stool sampling.\n* Association with another chronic pathology",true,{"count":19,"type":20},[23],"Spondyloarthritis (SpA) is a group of inflammatory rheumatic disorders that mainly manifested by inflammatory pain of the spine, pelvis and sometimes limbs. Classically, SpA has been classified into several subtypes, such as ankylosing spondylitis (AS), psoriatic arthritis (PsA), inflammatory bowel disease (IBD)-associated.\n\nSeveral studies have shown specific changes in the gut microbiota during SpA. A recent, uncontrolled study suggested that the therapeutic response to anti-TNFα (Tumor Necrosis Factor) therapy could be predicted by analysis of the gut microbiota.\n\nThe purpose of the study MEDIBIOTE 3 is to confirm that in SpA, the composition of the intestinal microbiota at the initiation of treatment is predictive of the response to treatment with biotherapy (anti-TNFα \u002F anti-IL17).",[116],"Spondyloarthritis",{"date":79,"type":32},{"date":119,"type":32},"2019-07-16",{"date":121,"type":20},"2026-05-15",{"name":38,"class":39},{"id":124,"slug":125,"hasResults":11,"nctId":126,"briefTitle":127,"officialTitle":128,"acronym":129,"eligibilityCriteria":130,"healthyVolunteers":111,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":131,"targetDuration":4,"studyType":73,"phases":4,"briefSummary":133,"conditions":134,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":136,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":40},"100372653","longitudinal-characterization-of-microbial-signature-in-systemic-sclerosis-patients-100372653","NCT04132206","Longitudinal Characterization of Microbial Signature in Systemic Sclerosis Patients","ScleroBiotique: Longitudinal Characterization of Microbial Signature in Systemic Sclerosis Patients","ScleroBiotique","Inclusion Criteria:\n\nFor ScS patients:\n\n1. Patients with ScS according to ACR criteria.\n2. Patients over 18 years old.\n3. Patients who have signed the consent to participate in this study.\n\nFor control subjects:\n\n1. Persons without diagnosis of ScS or any other chronic disease.\n2. Persons over 18 years old.\n3. Persons who have signed the consent to participate in this study\n\nExclusion Criteria:\n\n* 1\\. Persons with severe anemia (Hb \\\u003C 7 g\u002FdL). 2. Persons who cannot read French. 3. For control subjects: Persons with a particular symptom (as an example of digestive disorders), or under long-term treatment related to another pathology.\n\n  4\\. Persons treated with antibiotics, probiotics, prebiotics or any other treatment that may disrupt the gut microbiota within two months before stool sampling.\n\n  5\\. Persons referred to the article L1121-5 to 1121-8 of the Public health code, namely :\n* Pregnant, women in labour and breastfeeding mothers.\n* Persons deprived of their liberty by a judicial or administrative decision.\n* Persons undergoing psychiatric follow-up.\n* Minors\n* Persons of full-age who are subject to a legal protection measure or who are unable to express their consent.",{"count":132,"type":20},60,"Today, the study of gut microbiota has taken a prominent place in several fields of medical research. Numerous experimental data in humans and animals suggest that an imbalance in the composition of the microbiota could contribute to the pathophysiology of systemic autoimmune diseases such as Systemic Sclerosis (SCS). A future exploration of the microbiota, a source of diagnostic and\u002For prognostic biomarkers, may be very useful for tomorrow's medicine by proposing therapeutic interventions based on the correction of possible imbalances in the intestinal flora. Studies of the human gut microbiota in patients with ScS are limited to low-impact investigations, due to the lack of data on the clinical and biological characterization of the patients studied, and to the absence of longitudinal studies in the same patient. For this reason, we are interested in exploring the intestinal microbiota of ScS patients in a comprehensive and longitudinal way.",[135],"Systemic Sclerosis",{"date":79,"type":32},{"date":138,"type":32},"2019-10-08",{"date":140,"type":20},"2026-06-03",{"name":38,"class":39},{"id":143,"slug":144,"hasResults":11,"nctId":145,"briefTitle":146,"officialTitle":147,"acronym":148,"eligibilityCriteria":149,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":150,"enrollmentInfo":151,"targetDuration":4,"studyType":21,"phases":153,"briefSummary":154,"conditions":155,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":158,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":164,"locationsCount":165},"100563978","treatment-of-episodic-migraine-with-auricular-neuromodulation-100563978","NCT06623188","Treatment of Episodic Migraine With AURICular Neuromodulation","Treatment of Episodic Migraine With AURICular Neuromodulation: a Prospective Randomized, Placebo-controlled Study","MENAURIC","Inclusion Criteria:\n\n* 18 years ≥ Aged ≤ 60 years\n* Moderate to severe Migraine for at least one year\n* Migraines appeared before the age of 50 and diagnosed according to IHS (international headache society) criteria.\n* Therapeutic failure of at least 2 migraine preventive medications\n* Frequency of migraine days ≥ 4 per month and \\\u003C 15 per month\n\nExclusion Criteria:\n\n* Pathology of the auricle (e.g. epithelioma)\n* Patient treated with botulinum toxin for migraine ≤ 2 months\n* Patient treated with anti-cgrp for migraine, with last injection less than 3 months ago\n* Patient treated with non-invasive auricular stimulation ( TENS)","60 Years",{"count":152,"type":20},106,[23],"Migraine is a ubiquitous pathology affecting approximately 1 billion individuals and being the leading cause of morbidity worldwide before the age of 50. Migraine treatment consists of two main approaches: acute treatment to relieve headache symptoms and preventive treatment to reduce the frequency of migraine attacks by at least 50%. Preventive treatment involves medications such as beta-blockers, antiepileptics, calcium channel blockers, and a new therapeutic class called calcitonin gene-related peptide (CGRP) inhibitors. While traditional treatments have modest efficacy and limited tolerability, CGRP inhibitors have shown better tolerability and superior efficacy. However, their prescription in France is restricted to neurologists and specialized pain evaluation and treatment units. Additionally, the long-term effects of CGRP inhibition on blood pressure control and vascular homeostasis are not fully understood.\n\nIn addition to pharmacological preventive treatment, non-pharmacological approaches have emerged, such as auricular neurostimulation. This can be achieved through electrical stimulation of the cymba conchae, considered a non-invasive alternative to invasive vagal stimulation, and has shown benefits in reducing the number of migraine days compared to a placebo. Another approach involves stimulation of specific areas of the entire auricle using techniques borrowed from auriculotherapy (auricular acupuncture).\n\nThe objective of the study is to demonstrate that auricular neuromodulation, performed with a laser device, targeted and personalized on selected areas of the auricle, has a beneficial effect on the number of moderate to severe migraine days per month.",[156],"Migraine Disorders","2025-06-27",{"date":159,"type":32},"2025-07-01",{"date":161,"type":32},"2025-05-20",{"date":163,"type":20},"2027-11-20",{"name":38,"class":39},3,{"id":167,"slug":168,"hasResults":11,"nctId":169,"briefTitle":170,"officialTitle":170,"acronym":171,"eligibilityCriteria":172,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":173,"targetDuration":4,"studyType":21,"phases":175,"briefSummary":176,"conditions":177,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":179,"startDateStruct":180,"completionDateStruct":182,"leadSponsor":184,"locationsCount":40},"100541646","impact-of-onco-sexology-support-on-the-quality-of-life-of-patients-newly-diagnosed-for-cancer-100541646","NCT06332573","Impact of Onco-sexology Support on the Quality of Life of Patients Newly Diagnosed for Cancer","SEXOCARE","Inclusion Criteria:\n\n* Aged ≥ 18 years\n* Newly cancer diagnosis, including palliative care\n* Having given free and informed written consent\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding woman\n* Persons deprived of their liberty by a judicial or administrative decision.\n* Persons who are subject to a legal protection measure or who are unable to express their consent.",{"count":174,"type":20},168,[23],"Onco-sexology as a supportive care for patients treated for cancer is still rarely discussed or even non-existent in 2022. However, it's recommended to integrate the preservation of sexual health throughout the treatment and post-cancer process, given the impact of cancer, treatments and the importance of intimate life for a majority of patients.\n\nOnco-sexology is one of the supportive care services validated by The French National Cancer Institute (INCa). It is also an objective of the 2014-2019 cancer plan and the 2017-2030 national sexual health strategy plan.\n\nAlthough sexuality is one of the fundamental needs of the human being, including in the case of a chronic disease or cancer diagnosis, the lack of training of health professionals to deal with intimate life, the difficulty to exchange on this subject between caregivers and patients, the lack of financial support for onco-sexology consultations, are all obstacles to the global management of oncology patients. However, it's a request from patients to be able to discuss the subject in an intimate way with a professional.\n\nWhile onco-sexology is already recommended as supportive care, a study on the impact of the delay in the management of sexual difficulties on quality of life could provide a sufficient level of evidence to change the practices and the care pathway of the oncology patient. Our objective is to study whether early management in onco-sexology has an impact on quality of life compared to late management (ie onco-sexology consultation before vs. after introduction of systemic oncological treatment).",[178],"Cancer",{"date":159,"type":32},{"date":181,"type":32},"2025-04-22",{"date":183,"type":20},"2028-01-22",{"name":38,"class":39},""]